HeartBeam Inc. (NASDAQ: BEAT) will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss its first-quarter financial results for the period ended March 31, 2026. During the call, the company also plans to provide updates on key growth initiatives, including its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection and artificial intelligence programs. The announcement underscores HeartBeam's progress in advancing its 3D ECG technology platform, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025.
The limited commercial launch marks a significant milestone for the company, as it begins to introduce its cable-free, portable ECG device to the market. The device is designed to collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG, enabling physicians to identify cardiac health trends and acute conditions outside of medical facilities. This capability has the potential to redefine cardiac health management by delivering actionable heart intelligence wherever the patient is located.
In addition to the commercial launch, HeartBeam is developing an extended-wear patch that could further enhance continuous monitoring capabilities. The company's AI programs aim to improve the accuracy and speed of heart attack detection, leveraging machine learning algorithms to analyze ECG data. According to the press release, HeartBeam holds over 20 issued patents related to its technology enablement, providing a strong intellectual property foundation for its innovations.
Investors and analysts will be closely watching the earnings call for insights into the adoption rate of the limited commercial launch, the timeline for the extended-wear patch, and the potential impact of AI on HeartBeam's product portfolio. The company's ability to scale its technology and gain market traction will be critical factors in its growth trajectory. For more details on the intended use of HeartBeam's technology, refer to the cleared indications for use at https://www.heartbeam.com/indications. The latest news and updates on HeartBeam are available in the company's newsroom at https://nnw.fm/BEAT. The full press release can be viewed at https://ibn.fm/yN939.
